{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.39","value":"11.80"},{"groupId":"OG001","spread":"4.01","value":"9.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.","dispersionType":"Standard Deviation","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"MEAN","populationDescription":"PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to \"N=0\" for 80 mg QD arm within this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose","title":"Part 2: Apparent Clearance (CL/F) of GSK525762 After Repeat Dose Administration","type":"SECONDARY","unitOfMeasure":"Liters per hour"}